AngioDynamics (ANGO) announced enrollment of the first patient in the randomized study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical Limb Ischemia Below-the-Knee.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics meets primary endpoint in PRESERVE study
- AngioDynamics’ Strong FY25 Performance and Optimistic FY26 Outlook Support Buy Rating
- AngioDynamics initiated with a Buy at Lake Street
- AngioDynamics price target raised to $17 from $15 at Canaccord
- AngioDynamics Reports Strong Growth in Fiscal 2025